David Wright
Family Medicine · Austin, TXNPI 1487677282
Payments from drug & device makers
Across 277 payments — averaging $447.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$87K
- Merck$15K
- Janssen Products, LP$13K
- Viiv Healthcare Company$5K
- Theratechnologies Inc.$3K
- EMD Serono, Inc.$153
- plus $473 from 6 others
What the payments were for
- Consulting fees$23,30019%
- Speaking & faculty fees$84,29568%
- Travel & lodging$11,0469%
- Food & beverage$5,1794%
- Education$390%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 114 | $87,430 |
| Merck | 46 | $15,110 |
| Janssen Products, LP | 12 | $12,892 |
| Viiv Healthcare Company | 79 | $5,219 |
| Theratechnologies Inc. | 5 | $2,580 |
| EMD Serono, Inc. | 5 | $153 |
| Johnson & Johnson(2 entities) | 11 | $148 |
| Inspire Medical Systems, Inc. | 1 | $146 |
| Sanofi | 1 | $124 |
| AbbVie | 1 | $21 |
| Janssen Scientific Affairs, LLC | 1 | $20 |
| Eisai Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$123,859 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 137 | $521,905 |
| JulucaDolutegravir/Rilpivirine | 124 | $439,498 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 68 | $310,944 |
| TivicayDolutegravir Sodium | 80 | $308,124 |
| DescovyEmtricitabine/Tenofov Alafenam | 121 | $292,456 |
| DovatoDolutegravir Sodium/Lamivudine | 91 | $282,508 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 48 | $168,253 |
| PrezcobixDarunavir/Cobicistat | 67 | $160,201 |
| DelstrigoDoravirine/Lamivu/Tenofov Diso | 51 | $128,753 |
| Naloxone Hcl | 1,666 | $105,132 |
| IsentressRaltegravir Potassium | 16 | $45,594 |
| PifeltroDoravirine | 26 | $41,877 |
| EdurantRilpivirine Hcl | 23 | $33,550 |
| Maraviroc | 24 | $24,967 |
| OzempicSemaglutide | 26 | $23,994 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Viiv Healthcare CompanyJuluca, Tivicay, Dovato | $5,219 | $1,030,130295 claims |
| GileadBiktarvy, Descovy | $87,430 | $814,361258 claims |
| Janssen Products, LPSymtuza | $12,892 | $310,94468 claims |
| MerckDelstrigo, Isentress, Pifeltro, Belsomra | $15,110 | $221,024105 claims |
| Johnson & JohnsonPrezcobix, Xarelto | $148 | $166,60479 claims |
| Janssen Scientific Affairs, LLCEdurant | $20 | $33,55023 claims |
| AbbVieLinzess | $21 | $10,45416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Austin
- Cynthia BrinsonAustin$13.9M
- Gregg LucksingerAustin$11.4M
- Faith HolmesAustin$7.5M
- Gretchen CrookAustin$4.4M
- Matthew BrimberryAustin$3.8M
- Nomita KimAustin$3.3M
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.